Clinical trials of targeted toxins

Arthur E. Frankel, Edward P. Tagge, Mark C. Willingham

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Immunotoxins (monoclonal antibodies chemically coupled to peptide toxins) and fusion toxins (peptide ligands fused genetically to peptide toxins) have been used to treat a variety of malignancies over the last 20 years. Problems with normal tissue toxicities (vascular leak syndrome, hepatotoxicity, and neurotoxicities), poor penetration to tumor interstitum, and humoral immune responses have limited clinical efficacy. Higher response rates were observed with systemic therapy of leukemias and lymphomas and regional therapy of primary brain tumors. Ongoing studies are examining the role of targeted toxins in combination with chemoradiotherapy and in minimal residual disease settings.

Original languageEnglish (US)
Pages (from-to)307-317
Number of pages11
JournalSeminars in Cancer Biology
Volume6
Issue number5
StatePublished - 1995

Fingerprint

Immunotoxins
Clinical Trials
Peptides
Neurotoxicity Syndromes
Residual Neoplasm
Chemoradiotherapy
Humoral Immunity
Brain Neoplasms
Blood Vessels
Lymphoma
Neoplasms
Leukemia
Monoclonal Antibodies
Ligands
Therapeutics

Keywords

  • Diphtheria toxin
  • Fusion toxins
  • Immunotoxins
  • Pokeweed antiviral protein
  • Pseudomonas exotoxin
  • Ricin
  • Saporin

ASJC Scopus subject areas

  • Cancer Research

Cite this

Frankel, A. E., Tagge, E. P., & Willingham, M. C. (1995). Clinical trials of targeted toxins. Seminars in Cancer Biology, 6(5), 307-317.

Clinical trials of targeted toxins. / Frankel, Arthur E.; Tagge, Edward P.; Willingham, Mark C.

In: Seminars in Cancer Biology, Vol. 6, No. 5, 1995, p. 307-317.

Research output: Contribution to journalArticle

Frankel, AE, Tagge, EP & Willingham, MC 1995, 'Clinical trials of targeted toxins', Seminars in Cancer Biology, vol. 6, no. 5, pp. 307-317.
Frankel AE, Tagge EP, Willingham MC. Clinical trials of targeted toxins. Seminars in Cancer Biology. 1995;6(5):307-317.
Frankel, Arthur E. ; Tagge, Edward P. ; Willingham, Mark C. / Clinical trials of targeted toxins. In: Seminars in Cancer Biology. 1995 ; Vol. 6, No. 5. pp. 307-317.
@article{3f834adbe9604daa89a5700c837672f6,
title = "Clinical trials of targeted toxins",
abstract = "Immunotoxins (monoclonal antibodies chemically coupled to peptide toxins) and fusion toxins (peptide ligands fused genetically to peptide toxins) have been used to treat a variety of malignancies over the last 20 years. Problems with normal tissue toxicities (vascular leak syndrome, hepatotoxicity, and neurotoxicities), poor penetration to tumor interstitum, and humoral immune responses have limited clinical efficacy. Higher response rates were observed with systemic therapy of leukemias and lymphomas and regional therapy of primary brain tumors. Ongoing studies are examining the role of targeted toxins in combination with chemoradiotherapy and in minimal residual disease settings.",
keywords = "Diphtheria toxin, Fusion toxins, Immunotoxins, Pokeweed antiviral protein, Pseudomonas exotoxin, Ricin, Saporin",
author = "Frankel, {Arthur E.} and Tagge, {Edward P.} and Willingham, {Mark C.}",
year = "1995",
language = "English (US)",
volume = "6",
pages = "307--317",
journal = "Seminars in Cancer Biology",
issn = "1044-579X",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Clinical trials of targeted toxins

AU - Frankel, Arthur E.

AU - Tagge, Edward P.

AU - Willingham, Mark C.

PY - 1995

Y1 - 1995

N2 - Immunotoxins (monoclonal antibodies chemically coupled to peptide toxins) and fusion toxins (peptide ligands fused genetically to peptide toxins) have been used to treat a variety of malignancies over the last 20 years. Problems with normal tissue toxicities (vascular leak syndrome, hepatotoxicity, and neurotoxicities), poor penetration to tumor interstitum, and humoral immune responses have limited clinical efficacy. Higher response rates were observed with systemic therapy of leukemias and lymphomas and regional therapy of primary brain tumors. Ongoing studies are examining the role of targeted toxins in combination with chemoradiotherapy and in minimal residual disease settings.

AB - Immunotoxins (monoclonal antibodies chemically coupled to peptide toxins) and fusion toxins (peptide ligands fused genetically to peptide toxins) have been used to treat a variety of malignancies over the last 20 years. Problems with normal tissue toxicities (vascular leak syndrome, hepatotoxicity, and neurotoxicities), poor penetration to tumor interstitum, and humoral immune responses have limited clinical efficacy. Higher response rates were observed with systemic therapy of leukemias and lymphomas and regional therapy of primary brain tumors. Ongoing studies are examining the role of targeted toxins in combination with chemoradiotherapy and in minimal residual disease settings.

KW - Diphtheria toxin

KW - Fusion toxins

KW - Immunotoxins

KW - Pokeweed antiviral protein

KW - Pseudomonas exotoxin

KW - Ricin

KW - Saporin

UR - http://www.scopus.com/inward/record.url?scp=0029383662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029383662&partnerID=8YFLogxK

M3 - Article

C2 - 8562908

AN - SCOPUS:0029383662

VL - 6

SP - 307

EP - 317

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

SN - 1044-579X

IS - 5

ER -